Pre-warning Risk Scoring System for Sudden Cardiac Death
ConditionSudden Cardiac Death
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-90
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
About this trial
The goal of this observational study is to identify potential indicators for pre-warning of sudden cardiac death (SCD), including clinical biochemistry markers, electrocardiogram, echocardiography, MRI and CT imaging values, genetic markers and so on, and further construct a series of multi-parameter assessments of SCD early screening.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Coronary heart disease If there is a history of coronary heart disease or a new diagnosis of coronary heart disease, or with a report of coronary angiography that indicates at least one vascular stenosis>50%. Diagnosis includes chronic coronary syndrome (stable angina, ischemic cardiomyopathy, and occult coronary heart disease) and acute coronary syndrome (unstable angina, ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction).
Heart failure Individuals with a history of heart failure or newly diagnosed heart failure, including heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction (LVEF) ≤40%)、intermediate heart failure (HFmrEF, LVEF 41%-49%，with evidence of spontaneous or excitable increase in left ventricular filling pressure), and ejection fraction preserving heart failure (HFpEF, LVEF≥50%, there is evidence of spontaneous or excitable increase in left ventricular filling pressure).
Genetically related cardiomyopathy or arrhythmia Cardiomyopathy includes hypertrophic cardiomyopathy (DCM), dilated cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), inflammatory cardiomyopathy (myocarditis, sarcoidosis, Chagas disease). Hereditary arrhythmias include long QT syndrome, short QT syndrome, Brugada syndrome, idiopathic ventricular fibrillation, catecholamine sensitive polymorphic ventricular tachycardia (CPVT), early repolarization syndrome, etc.
Disqualifiers
Age<16 years old;
Refusal to the follow-up visits;
Individuals with severe mental disorders who are unable to express their wishes;
Other obvious physical diseases and abnormal laboratory test results;
Trial population
Participants with potential high-risk of sudden cardiac death.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Sudden cardiac death
Identify participants who die by cardiovascular diseases during follow-up period
Time frame
Baseline and to the 1-year, 2-year, 5-year follow-upSecondary outcomes
1
All-causes death
Identify participants who die during follow-up period
Time frame
Baseline and to the 1-year, 2-year, 5-year follow-up2
Recurrence of cardiovascular disease
Identify participants who with recurrence of cardiovascular disease during follow-up period
Time frame
Baseline and to the 1-year, 2-year, 5-year follow-up3
Cardiac arrest
Identify participants who suffer sudden cardiac arrest during follow-up period
Time frame
Baseline and to the 1-year, 2-year, 5-year follow-up4
Major cardiovascular events
Identify participants who suffer incident major cardiovascular events during follow-up period
Time frame
Baseline and to the 1-year, 2-year, 5-year follow-upSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov